Navigation Links
'Disappearing Stent is a Dream Come True' - World Leaders at India Live Cardiology Conference 2013
Date:3/7/2013

CHENNAI, March 7, 2013 /PRNewswire/ --

For its ability to unblock and then make arteries return to natural form, the recently launched bioresorbable vascular scaffold (BVS and also known as disappearing stent) is being hailed as the 4th revolution in management of coronary artery disease at India's biggest conference on interventional cardiology that took place at Hotel ITC Grand Chola, Chennai from February 27 to March 2, 2013.

Dr. Samin K. Sharma , Director, Clinical & Interventional Cardiology, Mount Sinai Medical Center, New York said, "If BVS is used in the treatment of coronary artery disease, the long term benefits are huge. Since the stent will leave body after 2 years after doing its work of clearing blockages, patient will not have to take blood thinning medicines lifelong and the vessels can return to its natural form making it work as per body needs. It is nothing less than a dream come true."

According to Dr. Mathew Samuel , father of Angioplasty, and Dr. Antonio Colombo , famously known as world leader in interventional cardiology from Italy, angioplasty with conventional stents has always carried the fear of clot because of stent called late stent thrombosis.

This is seen in about 10% of patients after 1 or 2 years. This problem is expected to be less if BVS is used.

"Unlike western world, the prevalence of heart disease is significantly high among young people in India. For these people, the dissolving stent is a blessing as they will no longer have to worry about any alteration in natural artery structure in their long life ahead," added Dr. Sharma

BVS or Absorb is a first-of-its-kind device for the treatment of coronary artery disease (CAD). It works by restoring b
'/>"/>

SOURCE India Live Cardiology
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
2. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
3. Bayer Submits New Drug Application for Riociguat for the Treatment of Pulmonary Arterial Hypertension and Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
4. Medicare Policies Are Inconsistent with Cost-Effective Aging-at-Home Strategies
5. Murray Dental Laboratory Deploys Jensen Dental CAD/CAM Solution for Increased Productivity, Higher Sales and More Consistent Restorations
6. Largest Prospective Study Shows IVUS-Guided Stent Placement Improves Patient Outcomes with Current Generation of Stents
7. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
8. U.S. Physician Survey: Stents by Brand, Length, Diameter, Type and Coating 2012
9. Terumo Completes U.S. Patient Enrollment in the OSPREY Trial to Evaluate the MISAGO Self-expanding Stent
10. Global Drug-Eluting Stents Industry
11. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... May 27, 2015 PharmaPoint: Type 1 Diabetes - ... Type 1 diabetes (T1D) is an autoimmune disease that ... that the body can no longer produce insulin. Over the ... at present, no other treatment can be offered to a ... insulin analogs with different times of action - long-acting as ...
(Date:5/27/2015)...  Precision Advisors ( www.precisionadvisors.com ), a Precision for ... Trends Study of 145 managed care executives. The study ... of big data and predictive analytics, but are not ... Health Information Technology for Economic and Clinical Health Act ... of electronic medical records (EMRs) by 2014. While a ...
(Date:5/27/2015)... May 27, 2015  LumiThera Inc., a developmental ... (PBM) treatment for ocular disorders and disease, announced ... Washington State Life Sciences Discovery Fund (LSDF) ... of the LSDF matching grants worth $500,000 to ... subjects with dry age-related macular degeneration (AMD). ...
Breaking Medicine Technology:PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 3PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 4Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data 2Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data 3LumiThera Receives LSDF Commercialization Grant Award 2
... New Somatropin Formulation Demonstrate Advantages ... Over Existing Once-Daily ... Nottingham, UK-based speciality pharmaceuticals,company, today announced that the successful ... the synthetic human growth,hormone (hGH) somatropin. Trials demonstrated therapeutic ...
... released by The Philadelphia AIDS Consortium:, WHO: ... its network of eleven (11) community-based organization,sites located ... 30 AmeriCorps ACTS members working throughout New,Jersey, Delaware ... 9 a.m. until Noon; Media Focused,Event 10:30 - ...
Cached Medicine Technology:Critical Pharmaceuticals Enter Sustained Release hGH Arena 2Unprecedented 8th Year Start Up of National Direct AmeriCorps Program Access to Care Through Service (ACTS) Parent, Lead Organization The Philadelphia AIDS Consortium and World Health Care Infrastructures 2
(Date:5/27/2015)... Beverly Hills, CA (PRWEB) May 27, 2015 ... state of the art web portal focussed on keratoconus ... disease. This relentless progressive disease has its onset in the ... quieting down. The cornea or the front clear part of ... withstand the pressure in the eye. It results in poor ...
(Date:5/27/2015)... Arizona (PRWEB) May 27, 2015 Continuing ... mission of healthier patients in the community, SmartPractice® ... Center (formerly John C. Lincoln). SmartPractice Vice President of ... Michelle Shaw presented a $25,000 check to Paulla Miller, ... HonorHealth’s Breast Health & Research Center on April 30. ...
(Date:5/27/2015)... May 27, 2015 Dr. Omar Ibrahimi, ... in Stamford, CT has been selected as part of ... physicians nationwide (and the only physician in Connecticut) to ... allows for the removal of submental fat (double chin). ... recovery time, no surgery and minimal risks. Dr. Ibrahimi ...
(Date:5/27/2015)... CURE® Magazine and the Bladder ... advance research, provide information and support, and raise awareness ... fifth most common type of cancer, which begins when ... out of control. , “CURE Magazine provides guidance ... the cancer experience through digital and print publications, live ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 CompanionDx ... pharmacogenomic and somatic genomic analysis in personalized cancer therapy: ... by the American Society of Clinical Oncology (ASCO) as ... 2 in Chicago. , The molecular and clinical data ... Genome Atlas (TCGA) database. The study reports improved patient ...
Breaking Medicine News(10 mins):Health News:KVI announced the launch of The Keratoconus website focused on age based keratoconus treatment . 2Health News:SmartPractice Donates $25,000 to HonorHealth Breast Health and Research Center 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3
... Million in Compensation and Benefits, MINNEAPOLIS, Dec. 6 ... William McGuire, today agreed to,terms with the UnitedHealth Special ... than $420 million in stock options and other,compensation to ... during,his tenure as CEO of the company, in addition ...
... against colorectal, prostate and oral tumors , , THURSDAY, ... from black raspberries, a fruit beverage and old-fashioned ... to treat or prevent different types of cancer, ... not been considered good treatments for chronic illness, ...
... Inc. (NYSE: WPI ), a leading ... reached a settlement with Novartis,Pharmaceuticals Corporation, Novartis ... and Proterra AG (collectively,"Novartis") on outstanding patent ... (rivastigmine tartrate) capsules., Under the terms ...
... (Nasdaq: NBIX ) announced today that the ... Veralliance Properties for its real estate,assets. Total consideration ... Concurrently with the closing of the transaction, Neurocrine,leased ... term, with renewal,options. Neurocrine also has certain options ...
... EXEL ) announced today that that it will hold ... of Hematology,48th Annual Meeting from 8:00 p.m. to 9:00 p.m. ... webcast and may be accessed in the Event Calendar,page under ... -- Michael Morrissey, PhD, President of Research & Development ...
... University of Pennsylvania School of Medicine and other ... care providers can better their chances of identifying ... the way they ask patients questions., In a ... Internal Medicine, researchers found a number of communication ...
Cached Medicine News:Health News:Dr. William McGuire Settles with the SEC and the UnitedHealth Group Special Litigation Committee on Stock Options Matter 2Health News:Dr. William McGuire Settles with the SEC and the UnitedHealth Group Special Litigation Committee on Stock Options Matter 3Health News:Green Tea, Fruit Extracts Touted as Potential Cancer Fighters 2Health News:Green Tea, Fruit Extracts Touted as Potential Cancer Fighters 3Health News:Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation 2Health News:Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets 2Health News:Reminder: Exelixis Announces December 10 Webcast of Its Analyst and Investor Briefing in Conjunction with The American Society Of Hematology 48th Annual Meeting 2Health News:Finding the right words: Provider-patient discussions can help domestic violence victims speak up 2
Midstream Catch Kits...
... a portable, noninvasive ultrasound instrument that measures ... use, and quickly provides accurate results. In ... the BladderScan® to obtain a precise reading ... supplies the information that caregivers need to ...
... The BladderScan® BVI 6100 is a handheld, ... It is easy to operate, so any ... accurately. To view ultrasound images from exams ... patient records and reimbursement, just log on ...
... BVM 6500 enables physicians ... determine UEBW (ultrasound estimated ... volume using 3-dimensional V-mode ... was designed to assist ...
Medicine Products: